Zoom, Kinsale Capital, Palantir And A Health Care Stock On CNBC's 'Final Trades'

On CNBC's “Halftime Report Final Trades,” Bryn Talkington, managing partner of Requisite Capital Management, said Zoom Communications, Inc. (NASDAQ:ZM) has high free cash flow.

Zoom, on Nov. 24, posted third-quarter revenue of $1.23 billion. It beat the consensus estimate of $1.21 billion. The company reported Q3 adjusted earnings of $1.52 per share, beating analyst estimates of $1.44, according to Benzinga Pro.

Bill Baruch, founder and president at Blue Line Capital, named Palantir Technologies Inc. (NASDAQ:PLTR) as his final trade.

On the earnings front, Palantir Technologies, on Monday, reported better-than-expected fourth-quarter financial results and issued first-quarter sales guidance above estimates. Also, the company issued FY26 sales guidance above estimates.

Don't forget to check out our premarket coverage here

Joshua Brown, co-founder and CEO of Ritholtz Wealth Management, picked Kinsale Capital Group, Inc. (NYSE:KNSL), saying the worst is already priced in and the stock should go higher.

Supporting her view, Wells Fargo analyst Hristian Getsov, on Jan. 15, initiated coverage of Kinsale Capital with an Overweight rating and set a $490 price target.

Joe Terranova, senior managing director for Virtus Investment Partners, recommended Merck & Co., Inc. (NYSE:MRK), a healthcare name.

According to recent news, Merck disclosed on Thursday that Health Canada has approved ENFLONSIA for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants.

Price Action:

• Kinsale Capital shares gained 0.4% to close at $410.44 on Thursday.
• Merck shares gained 1.2% to close at $119.75 during the session.
• Palantir shares fell 6.8% to settle at $130.01 on Thursday.
• Zoom shares declined 1.9% to settle at $89.08 during the session.

Image: Shutterstock